Clinical Trials Browser

Urothelial Cancer × enfortumab vedotin × 30 days × Clear all

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer